Kisspeptin-13 Improves Spatial Memory Consolidation and Retrieval against Amyloid-β Pathology

Document Type : Research article


1 Neuroscience Research Center, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2 Department of Physiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.


It has been shown that brain glucose metabolism impairment, obesity, and diabetes could
lead to cognitive decline and Alzheimer’s disease (AD) pathogenesis. Kisspeptin (KP) a G-protein
coupled receptor neuropeptide, has been suggested as a link between energy balance and
reproduction. Some studies have shown that the attenuation of KP signaling decreases metabolism
and energy expenditure. KP mRNAs and receptors are detected in the hippocampus
and cause the promotion of excitatory synaptic responses through modulation of postsynaptic
signaling. The purpose of this study was to investigate the effect of KP on spatial learning and
memory and its possible neuroprotective effect on Amyloid-Beta induced cognitive impairment
using the Morris Water Maze (MWM) task in rats. The reference and reversal spatial learning
and memory have been measured in this study. Rats were injected bilaterally by Aβ1-42 (2 μg/
μL) or saline as a vehicle into the hippocampal CA1 area. One week later, KP-13 (1.5 or 2 μg/
μL) was injected i.c.v before or after each training session for 3 days and memory was tested
24 h later. The results showed KP-13 by itself could significantly enhance spatial memory
consolidation and retrieval, and Aβ induced reversal and reference memory impairment was
significantly ameliorated by KP-13. In Conclusion, it seems that KP-13 as a neuropeptide has
to enhance spatial memory properties and could be a possible neuroprotective peptide on amyloid-
beta induced pathology.


Main Subjects

(1) Korolev IO. Alzheimer’s disease: a clinical and basic
science review. Med. Student Res. J. (2014) 4: 24–33.
(2) Selkoe DJ. Alzheimer’s disease is a synaptic failure.
Science (2002) 298: 789-91.
(3) Norfray JF and Provenzale JM. Alzheimer’s disease:
neuropathologic findings and recent advances in
imaging. Am. J. Roentgenol. (2004) 182: 3-13.
(4) Yamin G. NMDA receptor-dependent signaling
pathways that underlie amyloid beta-protein
disruption of LTP in the hippocampus. J. Neurosci.
Res. (2009) 87: 1729-36.
(5) Walsh DM, Klyubin I, Fadeeva JV, Cullen WK,
Anwyl R, Wolfe MS, Rowan MJ, and Selkoe DJ.
Naturally secreted oligomers of amyloid beta protein
potently inhibit hippocampal long-term potentiation
in-vivo. Nature (2002) 416: 535-9.
(6) Cunnane S, Nugent S, Roy M, Courchesne-Loyer A,
Croteau E, Tremblay S, Castellano A, Pifferi F, Bocti
C, Paquet N, Begdouri H, Bentourkia M, Turcotte E,
Allard M, Barberger-Gateau P, Fulop T and Rapoport
SI. Brain fuel metabolism, aging, and Alzheimer’s
disease. Nutrition (2011) 27: 3-20.
(7) Martins RN and Brennan CS. Neurodegeneration and
Alzheimer’s Disease: The Role of Diabetes, Genetics,
Hormones, and Lifestyle. 1st ed. John Wiley & Sons
Ltd., West Sussex, UK (2019) 1-7.
(8) Pasquier J, Kamech N, Lafont AG, Vaudry H,
Rousseau K and Dufour S. Molecular evolution of
GPCRs: Kisspeptin/kisspeptin receptors. J. Mol.
Endocrinol. (2014) 52: T101-17.
(9) Kotani M DM, Vandenbogaerde A, Communi
D, Vanderwinden JM, Le Poul E, Brezillon S,
Tyldesley R, Suarez-Huerta N, Vandeput F, Blanpain
C, Schiffmann SN, Vassart G and Parmentier M.
The metastasis suppressor gene KiSS-1 encodes 
kisspeptins, the natural ligands of the orphan G
protein-coupled receptor GPR54. J. Biol. Chem.
(2001) 276: 34631-6.
(10) Muir AI, Chamberlain L, Elshourbagy NA,
Michalovich D, Moore DJ, Calamari A, Szekeres
PG, Sarau HM, Chambers JK, Murdock P,
Steplewski K, Shabon U, Miller JE, Middleton
SE, Darker JG, Larminie CG, Wilson S, Bergsma
DJ, Emson P, Faull R, Philpott KL and Harrison
DC. AXOR12, a novel human G protein-coupled
receptor, activated by the peptide KiSS-1. J. Biol.
Chem. (2001) 276: 28969-75.
(11) De Bond JAP and Smith JT. Kisspeptin and energy
balance in reproduction. Reproduction (2014) 147:
(12) Dudek M, Ziarniak K and Sliwowska JH. Kisspeptin
and metabolism: the brain and beyond. Front.
Endocrinol. (Lausanne) (2018) 9: 145.
(13) Manfredi-Lozano M, Roa J and Tena-Sempere
M. Connecting metabolism and gonadal function:
novel central neuropeptide pathways involved in
the metabolic control of puberty and fertility. Front.
Neuroendocrinol. (2018) 48: 37-49.
(14) True C, Takahashi D, Kirigiti M, Lindsley SR,
Moctezuma C, Arik A, Smith MS, Kievit P
and Grove KL. Arcuate nucleus neuropeptide
coexpression and connections to gonadotrophinreleasing hormone neurones in the female rhesus
macaque. J. Neuroendocrinol. (2017) 29: 1-25.
(15) Andreozzi F, Mannino GC, Mancuso E, Spiga R,
Perticone F and Sesti G. Plasma kisspeptin levels
are associated with insulin secretion in nondiabetic
individuals. PLoS One (2017) 12: e0179834.
(16) Roa J and Tena-Sempere M. Connecting metabolism
and reproduction: roles of central energy sensors and
key molecular mediators. Mol. Cell. Endocrinol.
(2014) 397: 4-14.
(17) Lee DK, Nguyen T, O’Neill GP, Cheng R, Liu Y,
Howard AD, Coulombe N, Tan CP, Tang-Nguyen
AT, George SR and O’Dowd BF. Discovery of a
receptor related to the galanin receptors. FEBS Lett.
(1999) 446: 103-7.
(18) Arai AC and Orwig N. Factors that regulate KiSS1
gene expression in the hippocampus. Brain Res.
(2008) 1243: 10-8.
(19) Palasz A, Rojczyk E, Suszka-Switek A and
Wiaderkiewicz R. Neuroleptics affect kisspeptin
mRNA expression in the male rat hypothalamus and
hippocampus. Pharmacopsychiatry (2017) 50: 32-7.
(20) Mills EG, Dhillo WS and Comninos AN. Kisspeptin
and the control of emotions, mood and reproductive
behaviour. J. Endocrinol. (2018) 239: R1–R12.
(21) Telegdy G and Adamik Á. The action of
kisspeptin-13 on passive avoidance learning in
mice. Involvement of transmitters. Behav. Brain
Res. (2013) 243: 300-5.
(22) Jiang JH, He Z, Peng YL, Jin WD, Wang Z, Han
RW, Chang M and Wang R. Kisspeptin-13 enhances
memory and mitigates memory impairment induced
by Abeta1-42 in mice novel object and object
location recognition tasks. Neurobiol. Learn. Mem.
(2015) 123: 187-95.
(23) Yazdani H, Soltani Tehrani B and Babaei P. Effects of
kiss Peptin13 on spatial memory in streptozotocininduced alzheimer’s disease (AD) in Rat. J. Guilan
Univ. Med. Sci. (2016) 24: 54–62.
(24) Morris R. Developments of a water-maze procedure
for studying spatial learning in the rat. J. Neurosci.
Methods (1984) 11: 47-60.
(25) Pike CJ, Burdick D, Walencewicz AJ, Glabe CG
and Cotman CW. Neurodegeneration induced by
beta-amyloid peptides in-vitro: the role of peptide
assembly state. J. Neurosci. (1993) 13: 1676-87.
(26) Paxinos G and Watson C. The Rat Brain in
Stereotaxic Coordinates. 17th ed. Elsevier, Britain
(27) Davoodi FG, Motamedi F, Naghdi N and Akbari
E. Effect of reversible inactivation of the reuniens
nucleus on spatial learning and memory in rats using
Morris water maze task. Behav. Brain Res. (2009)
198: 130-5.
(28) Akbari E, Naghdi N and Motamedi F. The selective
orexin 1 receptor antagonist SB-334867-A impairs
acquisition and consolidation but not retrieval of
spatial memory in Morris water maze. Peptides
(2007) 28: 650-6.
(29) Gholamipour-Badie H, Naderi N, Khodagholi F,
Shaerzadeh F and Motamedi F. L-type calcium
channel blockade alleviates molecular and reversal
spatial learning and memory alterations induced by
entorhinal amyloid pathology in rats. Behav. Brain
Res. (2013) 237: 190-9.
(30) Delmas S, Porteous R, Bergin DH and Herbison
AE. Altered aspects of anxiety-related behavior in
kisspeptin receptor-deleted male mice. Sci. Rep.
(2018) 8: 2794.
(31) Chawla MK, Sutherland VL, Olson K, McNaughton
BL and Barnes CA. Behavior-driven arc expression
is reduced in all ventral hippocampal subfields
compared to CA1, CA3 and dentate gyrus in rat
dorsal hippocampus. Hippocampus (2018) 28:
(32) Arai AC, Xia YF, Suzuki E, Kessler M, Civelli O
and Nothacker HP. Cancer metastasis-suppressing
peptide metastin upregulates excitatory synaptic
transmission in hippocampal dentate granule cells.
J. Neurophysiol. (2005) 94: 3648-52.
(33) Arai AC. The role of kisspeptin and GPR54 in the
hippocampus. Peptides (2009) 30: 16-25.
(34) Mueller SG, Schuff N, Yaffe K, Madison C, Miller 
B and Weiner M. Hippocampal atrophy patterns in
mild cognitive impairment and Alzheimer’s disease.
Hum. Brain Mapp. (2010) 31: 1339-47.
(35) Thompson PM, Hayashi KM, Dutton RA, Chiang
MC, Leow AD, Sowell ER, De Zubicaray G,
Becker JT, Lopez OL, Aizenstein HJ and Toga AW.
Tracking Alzheimer’s disease. Ann. N.Y. Acad. Sci.
(2007) 1097: 183-214.
(36) Borbély E, Horváth J, Furdan S, Bozsó Z, Penke
B and Lívia F. Simultaneous changes of spatial
memory and spine density after intrahippocampal
administration of fibrillar Aβ1–42 to the rat brain.
Biomed. Res. Int. (2014) 2014: 1-9.
(37) Haghani M, Shabani M, Javan M, Motamedi F
and Janahmadi M. CB1 cannabinoid receptor
activation rescues amyloid beta-induced alterations
in behaviour and intrinsic electrophysiological
properties of rat hippocampal CA1 pyramidal
neurones. Cell Physiol. Biochem. (2012) 29: 391-
(38) Eslamizade MJ, Madjd Z, Rasoolijazi H,
Saffarzadeh F, Pirhajati V, Aligholi H, Janahmadi
M and Mehdizadeh M. Impaired memory and
evidence of histopathology in CA1 pyramidal
neurons through injection of Abeta1-42 peptides
into the frontal cortices of rat. Basic Clin. Neurosci.
(2016) 7: 31-41.
(39) De Felice FG. Alzheimer’s disease and insulin
resistance: translating basic science into clinical
applications. J. Clin. Invest. (2013) 123: 531-9.
(40) Zhang W, Bai M, Xi Y, Hao J, Zhang Z, Su C, Lei G,
Miao J and Li Z. Multiple inflammatory pathways
are involved in the development and progression
of cognitive deficits in APPswe/PS1dE9 mice.
Neurobiol. Aging (2012) 33: 2661-77.
(41) Monte SM. Brain insulin resistance and deficiency
as therapeutic targets in Alzheimer’s disease. Curr.
Alzheimer Res. (2012) 9: 35-66.
(42) Cao B, Rosenblat JD, Brietzke E, Park C, Lee
Y, Musial N, Pan Z, Mansur RB and McIntyre
RS. Comparative efficacy and acceptability of
antidiabetic agents for Alzheimer’s disease and
mild cognitive impairment: A systematic review
and network meta-analysis. Diabetes Obes. Metab.
(2018) 20: 2467-71.
(43) Choi EJ, Son YD, Noh Y, Lee H, Kim YB and Park
KH. Glucose Hypometabolism in hippocampal
subdivisions in alzheimer’s disease: a pilot study
using high-resolution (1)(8)F-FDG PET and 7.0-T
MRI. J. Clin. Neurol. (2018) 14: 158-64.
(44) Salari S and Bagheri M. A review of animal
models of Alzheimer’s disease: a brief insight
into pharmacologic and genetic models. Physiol.
Pharmacol. (2016) 20: 5-11.
(45) Malekzadeh S, Edalatmanesh MA, Mehrabani D
and Shariati M. Drugs induced Alzheimer’s disease
in animal model. Galen Med. J. (2017) 6: 185-96.
(46) Singh A and Kumar A. Comparative analysis of
intrahippocampal amyloid beta (1-42) and it is
intracerebroventricular streptozotocin models
of alzheimer’s disease: possible behavioral,
biochemical, mitochondrial, cellular and
histopathological evidences. J. Alzheimers Dis.
Parkinsonism (2016) 6: 1-7.
(47) Milton NG, Chilumuri A, Rocha-Ferreira E,
Nercessian AN and Ashioti M. Kisspeptin prevention
of amyloid-beta peptide neurotoxicity in-vitro. ACS
Chem. Neurosci. (2012) 3: 706-19.